Compare Citius Pharmaceuticals Inc (CTXR) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs DigitalOcean Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while DigitalOcean Holdings Inc trades at $122 (market cap $15.25B). The key difference: DigitalOcean Holdings Inc is far larger — about 814.2× Citius Pharmaceuticals Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | DOCN | |
|---|---|---|
Market Cap | $18.73M | $15.25B |
Sector | Health | Technology |
52-Week High | $1.82 | $181.29 |
52-Week Low | $0.48 | $29.99 |
Enterprise Value | $14.95M | $16.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
DigitalOcean (DOCN) trades at $124.15, up 1.57% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI demand, and raised full-year guidance. Valuation ratios are elevated, with a P/E of 56.43 and P/S of 13.99, reflecting high growth expectations. Analyst consensus is bullish with a $173.71 price target, though net cash flow turned negative in 2025 due to investing activities.
Outlook is positive given accelerating AI-driven revenue growth and profitability, but risks include high debt levels, competitive cloud market pressures, and stretched valuations. The stock offers upside if execution continues, but investors face volatility from earnings sensitivity and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
